Cargando…
The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells
Both erbB3 and IGF-1 receptor (IGF-1R) have been shown to play an important role in trastuzumab resistance. However, it remains unclear whether erbB3- and IGF-1R-initiated signaling pathways possess distinct effects on the sensitivity of lapatinib, a dual tyrosine kinase inhibitor against both EGFR...
Autores principales: | Lyu, Hui, Yang, Xiao He, Edgerton, Susan M., Thor, Ann D., Wu, Xiaoying, He, Zhimin, Liu, Bolin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823081/ https://www.ncbi.nlm.nih.gov/pubmed/26621843 http://dx.doi.org/10.18632/oncotarget.6404 |
Ejemplares similares
-
Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem
por: Wahdan-Alaswad, Reema, et al.
Publicado: (2020) -
Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo
por: Liu, Hao, et al.
Publicado: (2023) -
Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer
por: Wang, Shuiliang, et al.
Publicado: (2013) -
HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3
por: Chen, Jhen-Yu, et al.
Publicado: (2015) -
The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells
por: Huang, Jingcao, et al.
Publicado: (2013)